Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Axoltis Pharma holds a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently shows 1 pending office action, which is being reviewed by 1 distinct examiner. This indicates a highly focused prosecution phase with a single point of contact at the patent office.
The examination is confined to 1 distinct art unit, matching the 1 distinct examiner involved. SERGIO COFFA is the busiest examiner, holding 1 busiest examiner pending office action. Since the total pending office actions for the portfolio is 1, this examiner is responsible for the entirety of the company's current pending workload.
This concentration in 1 distinct art unit and under 1 distinct examiner suggests that the company's current patenting efforts are specialized. Practitioners managing this portfolio interact with only 1 distinct examiner, SERGIO COFFA, making the prosecution process relatively centralized. The 1 pending office action reflects a low volume of current administrative requirements within the Biotechnology & Pharmaceuticals sector, allowing for a targeted legal strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COFFA, SERGIO | 2 | 61.1% | +32.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17781214 | PEPTIDE COMPOSTIONS AND METHODS FOR TREATING TAUOPATHIES | COFFA, SERGIO | — |
| 17767099 | Systemic administration of peptides for the treatment of spinal cord injury and/or for remyelination | COFFA, SERGIO | — |
| Art Unit | Apps |
|---|---|
| 1658 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17781214 | PEPTIDE COMPOSTIONS AND METHODS FOR TREATING TAUOPATHIES | COFFA, SERGIO | 1658 | §103DP | Final Rejection | — | Pending | May 31, 2022 |
| 17767099 | Systemic administration of peptides for the treatment of spinal cord injury and/or for remyelination | COFFA, SERGIO | 1658 | §102 | Final Rejection | — | Pending | Apr 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAxoltis Pharma has 2 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sergio Coffa has the most, with 2 of Axoltis Pharma's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
